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Abstract
Following the introduction of effective protein-polysaccharide conjugate vaccines against
capsular group C meningococcal disease in Europe, meningococci of capsular group B
remain a major cause of death and can result in debilitating sequelae. The outer membrane
proteins PorA and FetA have previously been shown to induce bactericidal antibodies in
humans. Despite considerable antigenic variation among PorA and FetA OMPs in meningo-
cocci, systematic molecular epidemiological studies revealed this variation is highly struc-
tured so that a limited repertoire of antigenic types is congruent with the hyperinvasive
meningococcal lineages that have caused most of the meningococcal disease in Europe in
recent decades. Here we describe the development of a prototype vaccine against capsular
group B meningococcal infection based on a N. meningitidis isolate genetically engineered
to have constitutive expression of the outer membrane protein FetA. Deoxycholate outer
membrane vesicles (dOMVs) extracted from cells cultivated in modified Frantz medium con-
tained 21.8% PorA protein, 7.7% FetA protein and 0.03 μg LPS per μg protein (3%). The
antibody response to the vaccine was tested in three mouse strains and the toxicological
profile of the vaccine was tested in New Zealand white rabbits. Administration of the vac-
cine, MenPF-1, when given by intramuscular injection on 4 occasions over a 9 week period,
was well tolerated in rabbits up to 50 μg/dose, with no evidence of systemic toxicity. These
data indicated that the MenPF-1 vaccine had a toxicological profile suitable for testing in a
phase I clinical trial.
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Introduction
Meningococcal disease is a severe, potentially life-threatening infection, with highest incidence
among children less than five years of age. The incidence in high income countries has
decreased in recent decades, in part driven by the implementation of protein-conjugated poly-
saccharide vaccines providing protection against capsular group C meningococci [1], but per-
haps also as a result of environmental changes including reductions in smoking rates [2].
Changes in the meningococci circulating in asymptomatic carriage and changes in population
immunity may also have led to the decrease in disease incidence. Conjugate vaccines are avail-
able against meningococci expressing polysaccharide capsules of capsular groups A, C, Y and
W, which further reduce disease incidence where they are deployed. The development of a sim-
ilar capsular group B polysaccharide vaccine has been hampered by poor immunogenicity and
a concern about the risk of such a vaccine generating cross-reactive antibodies [3] against neu-
ral tissue [4].
To date, the most successful alternative vaccine formulations have included outer mem-
brane vesicles (OMVs) [5]: these vaccines are shown to be safe, moderately reactogenic, and
provide protection against outbreaks of capsular group B meningococcal disease caused by the
vaccine strain. However, their routine use against endemic disease is complicated by the high
degree of variation in sequence and expression levels among meningococcal outer membrane
proteins. The protection provided by OMV vaccines, made from the OMVs of wild type circu-
lating invasive meningococci (wt OMV vaccines), is largely attributed to their ability to induce
bactericidal antibodies to the immunodominant and antigenically variable outer membrane
protein (OMP) porin A (PorA) [5]. The challenge has been to produce a vaccine based on
OMP antigens that is broadly cross-protective against diverse meningococci. One approach
has been to supplement an OMV vaccine formulation with additional antigens identified from
genome sequence data such as the recently licensed Novartis vaccine, Bexsero [6]. In contrast,
utilizing the extensive epidemiological data available, we have proposed a multivalent OMV
approach based on two OMP antigens, PorA and FetA [7]. Molecular epidemiological studies
have shown that meningococcal antigenic diversity is structured by immunoselection, effec-
tively limiting the number of antigenic variants that would have to be included in a multivalent
vaccine to offer broad protection [8].
The outer membrane protein FetA is present in nearly all invasive meningococcal isolates,
and like PorA exhibits a high level of antigenic diversity [3]. Moreover, its expression is depen-
dent on the concentration of available free iron [9], consistent with its function as an iron
transporter [9]. FetA has, in previous studies, been shown to induce bactericidal antibodies in
animals and in humans following infection or vaccination with OMV vaccines [10–14]. The
bactericidal antibodies target one specific variable region (VR, ‘loop 5’) of the FetA protein [9]
which is immunodominant and shields the second most immunogenic domain (loop 3) [15].
The FetA content of wild-type OMV vaccines is, however, batch-variable, with relative protein
content 1–8% depending on the amount of available iron in the growth medium [16].
In the current study, we have generated a meningococcus that was constitutive for FetA
expression by genetic modification of the promoter region of the fetA gene to constitutively
express high levels of the protein. We demonstrate how a combined PorA and FetA vaccine
can be formulated from this strain to produce a PorA/FetA vaccine. Secondly, we demonstrate
the suitability of this vaccine concept for scale-up of manufacture, the toxicological profile of
the OMV in rabbits and impact of genetic variation on immune responses as demonstrated by
use of a well characterized panel of genetically engineered target N. meningitidis strains in the
bactericidal assay.
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Materials and Methods
Ethics statement
Animal studies were conducted according to the UK Home Office regulations under licence
number 80/2157 and were approved by the National Institute for Biological Standards and
Control ethics committee. Bleeds were taken under terminal anaesthesia. The GLP testing with
New ZealandWhite rabbits was performed under contract to Charles River, Edinburgh, United
Kingdom according to Good Laboratory Practice (GLP), relevant EMA guidelines (CPMP/
ICH/286/95, CPMP/SWP/465/95 and CHMP/SWP/488313/07), in accordance with licences
granted under the terms of the UK Animals (Scientific Procedures) Act 1986 and in compli-
ance with the European Directive 2010/63/EU. Potency testing of the vaccine in Norway was
undertaken according to the Norwegian Animal Welfare Act.
Generation of the vaccine strain and verification of expression and
genomic stability
The parent isolate for preparation of the vaccine strain was a capsular group B N. meningitidis
isolate, H44/76, derived from a patient who developed MenB disease in Norway in 1976 and
characterized as B:15:P1.7,16: F3-3: ST-32 (cc32) [16,17]. The H44/76 isolate used for this
study was a sub-culture previously received from NIPH and retained in the NIBSC strain col-
lection as strain 2851. Constitutive expression of fetA was achieved by replacing the native pro-
moter sequence with a novel promoter, based on the nucleotide sequences of the PorA and
PorB promoter regions. A 17bp spacer between the -10 and -35 sequences was found to result
in consistently high expression levels of FetA (Fig 1A).
The novel promoter was introduced by transforming the 2851 strain with the plasmid shown
in Fig 1B. Briefly, strain 2851 was resuspended from overnight growth on blood agar (Oxoid,
Cambridge, UK) to an OD650nm of 0.2–0.3 in 1ml Mueller Hinton broth (Oxoid) containing 8
mMMgCl2 (Sigma Aldrich, St Louis, Missouri, USA). Undigested plasmid DNA (1 μg) was
added to and the suspension was incubated at 37°C with 150 rpm rotational shaking for 4
hours. Cells were collected by centrifugation and plated onto Mueller-Hinton agar (Oxoid) con-
taining 50 μg/ml kanamycin (Sigma Aldrich) to select from plasmid integration. Kanamycin
resistant colonies were screened for the presence of the new promoter region by colony PCR.
PCR products were analyzed on a 0.8% agarose gel to check for band lengths, which were subse-
quently checked by nucleotide sequencing to confirm the presence of the promoter region.
The protein profiles of OMVs prepared by deoxycholate (DOC) detergent extraction as
described previously [18,19] were assessed on 8% SDS-PAGE (BioRad) run at 10 mA overnight
and stained with Silver Stain Protein kit (Amersham Biosciences). The effect of iron limitation
on FetA expression was also assessed by comparing membrane extracts for protein profiles, as
described above, derived from strains grown in Tryptone Soya Broth (TSB) with or without
50 μM deferoxamine mesylate (DFAM). Finally, the vaccine strain (3207) was assessed for
genetic stability, i.e. whether the inserted construct into the parent strain (2851) was stable
after consecutive passages. This was performed by growing strain 3207 on non-selective tryptic
soy agar (TSA) plates with Vitox (Oxoid), and comparing the number of colonies recovered on
selective (Kanamycin 50 μg/ml) and non-selective TSA plates through 10 consecutive passages.
Outer membrane protein preparations and genomic DNA preparations were then prepared
from before and after the 10 passages, with and without selective growth agar medium. Outer
membrane preparations were run on a 12% SDS-PAGE (Biorad), run at 10 mA overnight and
visualized by Coomassie staining. The nucleotide sequence of the promoter region of the fetA
gene was determined to assess potential variability as previously described.
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Generation of isogenic strains to evaluate vaccine immunogenicity
Three genetically modified N. meningitidis strains, with combinations of high and constitutive
expression of FetA and PorA or knockout mutants of these, were generated for use in serum
bactericidal activity (SBA) assay to evaluate PorA and FetA-specific vaccine responses follow-
ing vaccination of research animals and human volunteers (Table 1).
Strain 3043 had been transformed previously to interrupt expression of the FetA protein
[3]. To generate the two new mutants with interrupted expression of the full-length PorA
Fig 1. A. Genetic modification of N. meningitidis strains. Promoter region designed to alter expression levels of FetA. Spacer area (17 bp) indicated in grey
shading. Restriction enzyme sites for XbaI and BglII indicated along with -35 and -10 sequences. B. Schematic drawing of the plasmid used for
transformation of the N. meningitidis strain 2851 (H44/76), and the modified region in the transformed strains and the region amplified by the initial PCR
screening.
doi:10.1371/journal.pone.0134353.g001
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protein, strains SMenPF1.2 (3207) and 3043 were transformed with plasmid PorAEryF (Sand-
ers et al., unpublished observations). Meningococci were transformed as described above and
plated onto selective plates containing 50 μg/mL erythromycin (Sigma Aldrich). The expres-
sion of FetA and PorA in the three strains was verified as described above for the vaccine strain.
In addition, whole cells of the strain panel were tested by immunoblotting for binding with a
PorA-specific monoclonal antibody (Anti-P1.16, 01/538, NIBSC, Potters Bar, U.K.) or a FetA-
specific mouse antiserum. The latter was generated by immunization of NIH/OlaHsd mice
with recombinant FetA variant F3-3 protein (Sanders et al., unpublished observations).
Serum bactericidal activity
The suitability of the strain panel was further tested in serum bactericidal activity (SBA) assay,
using the tilted agar plate method and human complement as previously described [20]. Exoge-
nous human complement without intrinsic bactericidal activity was sourced from consenting
healthy adults and used at 25% (vol/vol) with each target strain having a single complement
source. Bacterial strains were grown overnight to single colonies on blood agar plates at 37°C
and 5% CO2. Approximately 50 colonies were then sub-cultured for 4 hours before being
reconstituted in Hanks buffered salt solution (Gibco) with 0.5% bovine serum albumin (Sigma
Aldrich). The bacteria were further diluted to give approximately 100 colony forming units per
10 μl used for the assay. The SBA titre was defined as the reciprocal of the highest dilution of
serum that yielded50% decrease in colony forming units relative to that of control wells
within 60 min at 37°C without CO2. Pools of sera from mice immunized with OMVs derived
from the vaccine strain SMenPF1.2 (batch FMOX1102) were tested in duplicate for their SBA
against the same panel, along with a PorA P1.16 mAb (NIBSC Cat. No. 01/538). The pools
were composed of all available sera from each test group: At release (0 months): for the saline
group n = 20, for the 2.5 μg group n = 20 and for the 10 μg group n = 10. After 12 months at
5°C and 2.5 μg dose: n = 19. After 24 months at 5°C and 2.5 μg dose: n = 20.
Impact of genetic modifications on vaccine and evaluation strains
Genomic DNA from the modified strains SMenPF1.2 (3207), 3043, 3311 3312 and parent
strain 2851 was extracted and purified using the Wizard Genomic DNA purification kit (Pro-
mega). Standard Illumina multiplex genomic libraries were prepared and sequenced on the
Illumina Genome Analyser II platform generating 100 bp paired end reads as previously
described [21]. Genome sequences were assembled using Velvet version 1.2.08 [22] with opti-
mal parameters determined by the Velvet-Optimiser script. Genomes were uploaded to the
Neisseria PubMLST isolates database (http://pubmlst.org/neisseria/) which is implemented
with the BIGSdb database platform [23]. When sequence data for each isolates record are
deposited in PubMLST, they are scanned against the definitions databases using the BLAST
Table 1. Meningococcal strains used in this study.
Strain Genotype PorA expression a FetA expression a Source
SMenPF1.2 (3207) b H44/76 fetAp17bp Wild-type and high Constitutive This study
3043 H44/76 fetA::kan Wild-type and high Absent [28]
3311 H44/76 fetA::kan porA::ery Absent Absent [Sanders et al., unpublished observations]
3312 H44/76 fetAp17bp porA::ery Absent Constitutive [Sanders et al., unpublished observations]
a Expression levels of major outer membrane proteins PorA and FetA are indicated.
b The vaccine strain SMenPF1.2 is the master seed lot that was prepared under GMP conditions from the strain 3207.
doi:10.1371/journal.pone.0134353.t001
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algorithm. When a known allele is identified, it is recorded as a designation for that locus in the
isolate record, and the position of the allele in the contig is marked (tagged) [24]. Using the
GenomeComparator tool, the four isolates as well as the parent strain were compared for genes
related to the major antigens in the vaccine (FetA, PorA, PorB, LPS) and all loci defined in the
FAM18 genome annotation [25]. Repetitive sequences due to multiple copies of insertion ele-
ment transposases and pseudogenes were removed when using the FAM18 annotation as the
source of comparator coding sequences. Paralogous loci that matched multiple alleles were also
removed from the analysis. Sequence conflicts were checked by remapping using the Bowtie
version 1 short-read aligner [26]. For a specific locus of interest, the contig containing the locus
was extracted from the isolate sequence bin and used as the reference segment. Short-reads for
each isolate being investigated were converted to SAM files and mapped against the reference
segment using a randomized alignment in order to avoid mapping bias. The aligned SAM files
were visualized using the Tablet software package [27] and read depth and conflicting nucleo-
tides of interest were identified and examined. CGView was used to visualize the locus posi-
tions in the circular H44/76 genome [28].
GMP production of OMVs, final vaccine product and GLP study control
product
A GMP production process for OMV extraction was established at the Biomanufacturing unit
at the NIPH, Oslo, Norway based on experiments at OVG, Oxford, U.K. and on experience of
the Norwegian MenBvac vaccine production process [18]. After passaging the vaccine strain
SMenPF1.2 three times on TSA+Vitox agar plates certified to be TSE/BSE-free, a seed lot was
produced and evaluated in Oxford for growth characteristics at the same scale as to be per-
formed at NIPH, performed in shaking flasks with a growth medium volume ranging from 0.2
to 1.5 L in modified Frantz medium [17] and to finalise the process parameters. Meningococci
from the working seed bank (WSB) were spread to confluent growth on TSA plates with Vitox
growth supplement (Oxoid, U.K.), incubated at 35°C and 5% CO2 using anaerobic jars for 12–
24 hours, harvested in 10 mL modified Frantz medium [17] and used to inoculate 1–1.5L
Frantz medium in single-use 2800 mL baffled shaking flasks (Nalgene, U.S.) Fig 2).
Growth with shaking was performed at 35°C and 150–200 rpm for 5–8 hours, and thereafter
the bacterial suspension was harvested into a sterile 10 L flask. The culture was sampled for
yield (OD at 650 nm) and purity by testing with Gram stain and growth on TSA and plate
count agar plates. Concentration of the cell mass was performed in a class II biosafety cabinet
in a P3 GMP laboratory facility by cross-flow filtration (CFF) using a Millipore CFF filter until
a final volume of 0.6–1.1 L was reached. pH adjustment was performed by adding 0.1 M Tris/
HCl (pH 8.6) with 10 mM EDTA (buffer A), and a second buffer (10% sodium deoxycholate
(DOC) in Tris/HCl, pH 8.9; buffer A1) was added to obtain a final concentration of 0.5%
DOC; leading to the inactivation of the cell mass and extraction of OMVs. An equal volume of
Buffer A was slowly added, homogenized by magnet stirring and pH measured to ensure a
pH> 8.0. Ninety mL of Buffer A1 was slowly added and the suspension was kept homogenous
by stirring for 30 minutes and then sampled to check the inactivation procedure. Cell debris
was removed by centrifugation at 12000 rpm for 90 minutes at 2–8°C, supernatants were
pooled and centrifuged at 19000 rpm for 10 hours. The pellet was suspended in a 1:2 mix of
buffers B (0.05 M Tris/HCl, 2 mM EDTA, 2.5% DOC) and buffer B1 (0.05 M Tris/HCl, 2 mM
EDTA, 0.5% DOC, 30% sucrose) and homogenized by magnetic stirring for 5 hours or over-
night at room temperature and sonication for 1 minute. The suspension was then subjected to
a new centrifugation at 19000 rpm for 5 hours, for thereafter to suspend the pellet in a 3%
sucrose solution. Homogenisation was ensured by magnetic stirring for 5 hours or overnight at
Meningococcal OMV Vaccine with Constitutive FetA Expression
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room temperature and sonication for 1 minute. The OMVs were diluted in 3% sucrose solution
to obtain a final protein concentration of about 1 mg/mL, briefly sonicated and filtered using a
MiniKleenPak capsule with 0.2 μm Supor EKV polyethersulfone low-protein-binding membrane
filter (Pall corporation, U.S.). The OMVs were adsorbed to the adjuvant aluminium hydroxide
(Brenntag, Denmark), suspended in a 3% sucrose solution, diluted to an end concentration of
50 μg protein/mL and ultimately filled in sealed, capped and labelled 2R injection vials for single
dose-use with an injection volume of 0.5 ml (equals 25 μg of OMV protein, 12.5 mg sucrose and
0.333% w/v aluminum hydroxide in water for injection). Three GMP batches were produced;
FMOX1002, FMOX1005 and FMOX1007, which were stored at 5°C (± 3°C) until use.
A control vaccine product was specifically manufactured for the GLP immunotoxicological
study in rabbits, using the same reagents and equipment as for the vaccine product and accord-
ing to GMP regulations. The product (termed MOX Control) contained a suspension of alu-
minium hydroxide (0.333% w/v) diluted in 3% sucrose in water for injection and was tested for
extractable volume, sterility, aluminum content, pH, endotoxin level and appearance; with the
same specifications for these parameters as for the final vaccine product (Table 2).
Fig 2. Meningococcal cultivation procedures. A. The ideal growth times on agar plates under production
of Seed Lots were 10–12 hours for the 1st passage, 7–8 hours for the 2nd passage, and 6–8 hours for the 3rd
passage at 35°C. When cultivated in 1.5L medium in 2.8 L shaking flasks, shaking speed 200 rpm and
temperature 35°C and an initial OD650 = 0.1, the length of the lag phase was approximately 2 hours, whereas
the log-phase seemed to end at 7–8 hours with an OD650 of ~2. B. Comparison of growth in 1.0 L modified
Frantz liquid medium in a 2L baffled shaking flask for the strains 3208 (MenPF-1 vaccine strain) and the 2851
strain (wild type H44/76 strain).
doi:10.1371/journal.pone.0134353.g002
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Quality control testing of OMVs and adsorbed vaccine
The analytical methods used for quality control of the active pharmaceutical ingredient
(OMV) and the vaccine final product (MenPF-1) are given in Table 1, along with acceptance
criteria. The OMVs were characterised for their antigenic composition by 12.5% SDS-PAGE
stained with Coomassie blue, as previously described [19], and compared with OMVs used as
Table 2. Acceptance criteria and results from quality control testing of OMVs and final vaccine product MenPF-1.
I. OMVs Batch name
Parameter Speciﬁcation Method MOX1101 MOX1104 MOX1106
Inactivation
control
Inactivated material Pass Pass Pass
Total protein pre-
formulation
To be reported Folin Lowry 0.74 mg/mL 0.80 mg/mL 0.84 mg/mL
Bioburden, pre
sterile ﬁltration
Total aerobic microbial count (TAMC);
Total yeasts and moulds count (TYMC)
and total bioburden: all <101/mL
Pass Pass Pass
Identity, antigen
pattern
To be reported SDS-PAGE Ph. Eur.
2.2.31
FetA: 8.0, PorA:
21.7 and PorB:
32.6
FetA: 7.3, PorA:
21.5 and PorB:
33.0
FetA: 7.7, PorA:
21.8 and PorB:
31.9
Identity,
presence of
antigens
Verify detection of 70 kDa (FetA F3-3),
Class 1 (P1.16) and Class 3 (P3.15)
with antigen speciﬁc monoclonal
antibodies
Immunoblotting with
speciﬁc antibodies
Detected Detected Detected
Deoxycholate <0.4 μg/μg protein Total Bile Acid Assay,
Bio-Stat
0.26 0.20 0.20
LPS content Total content: <0.12. LPS L3,7,9: to be
reported
SDS-PAGE, silver
staining and digital
scanning
Total content: 0.044
and L3,7,9 content:
0.043
Total content: 0.024
and L3,7,9 content:
0.024
Total content: 0.030
and L3,7,9 content:
0.030
Total protein 0.45–1.24 mg/mL Folin Lowry 0.60 0.65 0.86
Appearance Turbid, white to yellow, even
suspension, easily redispersed
Ph. Eur. 20920 Pass Pass Pass
pH To be reported Ph. Eur. 2.2.3 7.3 7.4 7.5
II. Final product
Parameter Speciﬁcation Method FMOX1102 FMOX1105 FMOX1107
Aluminium < 1.25 mg/ml Ph. Eur 0153 1.0 1.1 1.0
Endotoxin < 1 x 105 IU/ml Ph. Eur. 2.6.14 < 1 x 105 IU/ml <0.5 x 105 IU/ml < 1 x 105 IU/ml
Identity Verify detection of 70 kDa (FetA F3-3),
Class 1 (P1.16) and Class 3 (P3.15)
with antigen speciﬁc monoclonal
antibodies
Ph. Eur. 2.2.31 Detected Detected Detected
pH To be reported * Ph. Eur. 2.2.3 6.1 5.9 6.1
Potency To be reported ** In-house 2067 (1509–2839) 3027 (2239–4091) 2741 (1778–4224)
Pyrogenicity Pass Ph. Eur. 20608 Pass Pass Pass
Sterility Pass Ph. Eur. 20601 Pass Pass Pass
Appeareance Opaque, even, milky Ph. Eur. 20920 Pass Pass Pass
Extractable
volume
0.50 mL Ph. Eur. 2.9.17 Pass Pass Pass
Degree of
adsorption
To be reported Ph. Eur. 01503 >93% >93% >93%
*For comparison the pH of MenBvac has been in the range 5.5–7.0 (unpublished observations, NIPH).
** Data presented in Fig 6. The relative IgG antibody response against OMVs is here reported as Geometric mean titre (GMT) and 95% conﬁdence
intervals (Arbitrary Units of anti-OMV IgG/mL) in serum after 2 doses of 2.5 μg OMV protein 3 weeks apart, 2 weeks after last dose.
doi:10.1371/journal.pone.0134353.t002
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the active pharmaceutical ingredient in the Norwegian capsular group B vaccine MenBvac
[17]. The relative content of proteins that were either present in high amount and/or regarded
as relevant for immunological protection were quantified by densitometric digital scanning
(BioRad), i.e. FetA, PorA and PorB. The LPS content of OMVs was quantified by densitometric
scanning of silver stained tricine-SDS PAGE gels. The final vaccine product was tested for
appearance, pyrogen content, protein content, potency (i.e. immunogenicity), endotoxin level,
sterility, pH and degree of adsorption [18] (Table 2). In addition, the three first batches pro-
duced were tested for the abnormal toxicity test according to Ph. Eur 20609. A stability study
evaluated if the OMV vaccine final product was able to meet the acceptance criteria at normal
(5°C) and accelerated (25°C) conditions over 24 months (Table 3).
The ability of the batches to induce bactericidal antibodies was assessed by SBA on pools of
sera frommice immunized with batch FMOX1102 on release (mice receiving either zero, 2.5 μg
or 10 μg OMV), after 12 and 24 months stored at 5°C (both tested at 2.5 μg doses) and after 6
months stored at 25°C. Batch FMOX1107 was similarly tested after 24 months stored at 5°C.
Potency testing and comparative immunogenicity in three mouse strains
Potency testing of 3 batches of the final vaccine product (FMOX1002, FMOX1005 and
FMOX1007) was performed to assess the dose-response curve in mice. Groups of 10 female,
inbred NIH Ola/Hsd mice (12–14 g) (Harlan, U.K.) were immunised sub-cutaneously with
one of four dose levels (1, 2.5, 5 or 10 μg OMV protein) of OMV vaccine final product. In each
experiment (one per batch), a negative control group (five mice) was immunized with a control
vaccine consisting of aluminum hydroxide in sucrose solution (MOX Control). Two doses
(each in 0.5 mL volume) were administered 3 weeks apart, with blood samples drawn 3 weeks
after the second dose (day 42 after 1st dose, d42). The antibody responses were assessed by use
of OMV ELISA as previously described [19] using OMVs from GMP batches as the coating
antigen. Recombinant PorA and FetA antigens for ELISA were provided by Hema Patel
(NIBSC) and refolded from inclusion bodies using protocols described elsewhere [29]. Pools of
sera were further analysed in SBA against the capsular group B vaccine strain panel as
described in previous sections.
To assess the potential impact of strain variation on the immunological response, the immu-
nogenicity of the final vaccine product was assessed in three different mouse strains, using lab-
oratory scale OMVs prepared from the working seed lot of the vaccine strain SMenPF-1.2.
Groups of 10 mice (female, 18–22 g) of three different mouse strains (NIH Ola/Hsd, Balb/c
and C57/Black) were immunised subcutaneously with two doses of 2.5 μg OMV protein
adsorbed to Al(OH)3 (1/10th of human dose) in an injection volume of 0.5 mL. Doses were
given 3 weeks apart, and blood sampled 3 weeks after the second dose. Sera were analysed for
Table 3. Stability of three batches of the final product evaluated at normal (5°C) at 24 months and accelerated (25°C) conditions at 6 months.
Test Speciﬁcation FMOX1102 FMOX1105 FMOX1107
5°C 25°C 5°C 25°C 5°C 25°C
Aluminium < 1.25 mg/ml 1.0 1.1 1.0 1.0 1.1 1.0
Endotoxin < 1 x 105 IU/ml < 1 x 105 IU/ml <0.5 x 105 IU/ml < 1 x 105 IU/ml < 1 x 105 IU/ml <0.5 x 105 IU/ml < 1 x 105 IU/ml
pH To be reported 6.1 5.9 6.1 6.1 5.9 6.1
Potency data are shown in Fig 6. Acceptance criteria for tests speciﬁc for identify (detection of 70 kDa (FetA F3-3), Class 1 (P1.16) and Class 3 (P3.15)
proteins), pyrogenicity, sterility, appearance (opaque, even, milky) and extractable volume (0.50 mL) passed for all 3 batches, and degree of adsorption
was >93% for all.
doi:10.1371/journal.pone.0134353.t003
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IgG against vaccine strain OMVs or recombinant FetA protein (VR 3–3) by ELISA, including
IgG2 subclass responses.
Toxicological evaluation of final OMV vaccine
The non-clinical safety assessment of the final vaccine product was performed to assess its suit-
ability for testing in a future phase I clinical trial. The GLP testing was performed under con-
tract to Charles River, Edinburgh, United Kingdom according to Good Laboratory Practice
(GLP), relevant EMA guidelines (CPMP/ICH/286/95, CPMP/SWP/465/95 and CHMP/SWP/
488313/07) and to the U.K. Animal Welfare Act (2006). The testing was performed in one gen-
eral toxicology study for local tolerance and repeated dose in rabbits. The test scheme was
designed to support the clinical administration of up to three intramuscular doses of the
MenPF-1 vaccine, either in 25 μg or 50 μg total protein dose levels (Table 4).
The objective of the toxicology study was therefore to determine the potential toxicity of
vaccine when given by intramuscular injection on 4 occasions over a 9 week period to New
Zealand white rabbits to evaluate the potential reversibility of any findings. The vaccine prod-
uct evaluated in the GLP toxicity test (batch FMOX1102) had passed the same relevant specifi-
cations as for the GMP batch to be used in the clinical phase I trial (FMOX1107; Table 2). A
placebo product was used as comparator in the study, containing a suspension of aluminum
hydroxide (0.333% w/v) diluted in 3% sucrose in water for injection (MOX Control, lot
FMOX1102). In total 36 rabbits (18 male and 18 female) were injected into a hind limb muscle
on Days 1, 22, 43 and 64 with necropsy on Days 66 and 92. Of the 36 animals, 12 were treated
with a control preparation containing the same adjuvant and excipients as the test vaccine. The
following parameters and end points were evaluated: viability, clinical signs, injection site reac-
tions, body weights, body weight changes, food consumption, ophthalmology, body tempera-
tures, clinical pathology parameters (haematology, coagulation and clinical chemistry),
antibody analysis, gross necropsy findings, organ weights and histopathological examinations
(S1 Text).
Statistical analyses
Differences in antibody levels or SBA titers levels between groups were analysed using non-
parametric statistical tests using GraphPad Prism Version 5 (GraphPad Software, CA, U.S.).
Correlations were assessed by the Spearman rank order correlation test. The statistical analyses
in the GLP toxicology study were performed two-sided and at the 5% significance level. Male
and female animals were analysed separately. Pairwise comparisons were performed against
the control group. Body weight, food consumption, haematology, coagulation and clinical
chemistry were analysed for homogeneity of variance using the ‘F Max' test, with specified pro-
cedures according to the homogeneity of the group variances involving use of parametric
ANOVA, Fisher’s F protected LSD method via Student's t test, Kruskal-Wallis non-parametric
ANOVA or chi squared protection. Organ weights, and organ weights as a percentage of
Table 4. Experimental design of the GLP toxicity study of MenPF-1 in New Zealand white rabbits.
Main Study Recovery Test Item Dosage (μg/dose) Conc. (μg/mL) Dose Volume (mL/dose)
Group No. M F M F
1 1–3 10–12 19–21 28–30 MOX Control 0 0 0.5 mL
2 4–6 13–15 22–24 31–33 MenPF-1 25 50 0.5 mL
3 7–9 16–18 25–27 34–36 MenPF-1 50 50 2 x 0.5 mL
doi:10.1371/journal.pone.0134353.t004
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terminal body weight, were analysed using ANOVA and by analysis of covariance (ANCOVA)
using terminal kill body weight as covariate.
Results
Construction of vaccine strain and verification of suitability for OMV
production
Ameningococcal strain was genetically modified to express the FetA protein, regardless of the
amount of available iron, by replacing the wild-type promoter region of the fetA gene with a
constitutive promoter containing a 17 bp spacer region between its -10 and -35 sequences. The
strain used for this genetic modification expressed PorA at a high level that was retained after
the modification of FetA expression (Fig 3).
When tested for stability of FetA expression in various growth media, it was found to appear
independent of iron content in the growth medium as compared to the wild type strain 2851
(Fig 3). The vaccine construct was stable, as the mutant showed consistently upregulated FetA
expression after 10 consecutive passages with or without kanamycin selection (data not
shown). Furthermore, the strain showed good growth characteristics as measured by viability
before and after processing into seed lots and growth in 1.5 L modified Frantz liquid medium
(108 to 109 CFU/mL) (Fig 2), whilst retaining its expression of key antigens FetA, PorA, PorB
and LPS.
Taken together these observations verified the suitability of SMenPF1.2 as a vaccine
manufacturing strain. The cross flow filtration process showed that depending on the concen-
tration of bacteria after incubation in shaking flasks, the bacterial suspension could be concen-
trated 8–15 times. Three GMP batches of OMVs were produced (FMOX1102, FMOX1105,
FMOX1107) with mean protein concentration pre-formulation of 0.79 mg/mL (CV 5.2%)
(Table 2).
Characteristics and stability of the OMV vaccine
Quality control data were generated for the three vaccine batches (Table 2). These demon-
strated that FetA was elevated compared to iron replete conditions in the OMVs, and that this
did not vary between batches (mean 7.9% FetA protein relative to total protein bands, CV
9.1%). The protein content of the vaccine was found to be consistent between the three batches
of OMVs, with mean PorA content of 21.7% (CV 0.6%), and mean PorB content of 32.5% (CV
1.4%), whereas the LPS content relative to protein (acceptance criteria<12%) showed larger
variation (range 2.4 to 4.4%, CV 26%) (Fig 4).
Electron microscopy (EM) analysis to provide morphological characterization was not part
of the acceptance criteria, and was performed on one bulk OMV batch (MOX1106) as the 3
batches were otherwise comparable (Table 2). EM demonstrated the presence of both intact
and fragmented vesicles, with intact vesicles in the size range of approximately 40–140 nm (Fig
5).
Stability studies verified that the acceptance criteria could be met after 24 months of storage
at normal conditions (5°C), and at accelerated conditions (25°C) for up to 6 months (Table 3).
Immunogenicity evaluation in three mouse strains and in potency
studies
The potency studies showed that the vaccine elicited dose-responsive OMV specific antibodies
(Fig 6).
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A comparison of the immunogenicity in three inbred mouse strains (NIH, Balb/c and C57/
Black) with two doses of 2.5 μg OMV protein (1/10th of the human dose) showed that there
was no significant difference between the three mouse strains in their IgG response. Antibody
responses with this dose level induced IgG against whole cells of the vaccine strain, recombi-
nant PorA and FetA (Fig 7). There were no statistically significant differences between mouse
strains, apart from the IgG2 response against whole cells being higher in NIH mice than in
Balb/c and C57/Black mice.
Product characteristics upon release and following storage for 24
months
Stability testing included two dose levels; 1 and 2.5 μg protein per dose. For all three batches
(FMOX1102, FMOX 1105 and FMOX 1107), samples were stored for 24 months at 5°C, and
for 6 months at 25°C. All tests yielded results that met the release specification requirements.
No significant change was observed for pH in this time period (Table 3), and potency remained
high for all 3 batches over 24 months (Figs 8 and 9). However, some reduction in potency was
Fig 3. Effect of iron restriction and consecutive passages on FetA expression in OMVs from strain
3208, as analysed by gel electrophoresis of protein extracts. Silver stained resolving gel of OMVs
prepared from the parent and transformants. Lanes: (adjusted to 10ug protein per well). Lane 1: BioRad pre-
stained SDS broad-range standards. Lane 2: Wildtype (2851)–not iron restricted. Lane 3: Wildtype (2851)–
iron restricted. Lane 4. Constitutive Strain (3207)–not iron restricted. Lane 5: Constitutive Strain (3207)–iron
restricted.
doi:10.1371/journal.pone.0134353.g003
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observed for batches FMOX1105 between release to 12 and 24 months (GMT fell from 3027 to
2141 to 1539, respectively) and FMOX1107 between 12 and 24 months (GMT fell from 4075 to
2215) (Fig 9).
The adsorption to adjuvant was consistent during the stability study, indicating that the pre-
dicted immunological activity was also stable for 24 months.
Toxicological evaluation
Results from the evaluation of potential toxicity and reversibility of reactions to the vaccine
MenPF-1 (lot FMOX1102) when given by intramuscular injection for 4 occasions over a
9-week period to New Zealand White rabbits showed that there were no unscheduled deaths
during the observation period (S1 Text). There were no systemic signs and no local irritation
noted in any animal during the observation period. Body weight and food consumption pro-
files were unaffected by treatment and there were no eye changes that were considered to be
treatment related. There were no differences in body temperatures recorded up to 48 h after
injection with MenPF-1. Other than higher neutrophil numbers, higher fibrinogen levels and
minor disturbances in plasma proteins at Day 64 in animals that received MenPF-1, when
compared with controls, there were no in-life findings that were considered to be related to
treatment with the vaccine.
Fig 4. Antigen characterization. A. Binding of monoclonal antibodies (PorA P1.16 (01/538), PorB P3.15 (02/310) and LPS L3,7,9 (01/412)) and antisera
(FetA F3-3 (12/03/2010)) to a whole cell preparation of a sample of SMenPF1.2 from a Frantz 7h liquid culture, separated by 12% SDS-PAGE and
electrotransferred to nitrocellulose membrane. B. Antigen profile of the drug substance in the MenPF-1 vaccine (lot MOX1106), as determined by gel
electrophoresis. Arrows indicate molecular weight standard (Amersham). C. Relative protein content of three batches of OMVs derived from vaccine strain
SMenPF1.2.
doi:10.1371/journal.pone.0134353.g004
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At Day 66 (2 days after the last injection), 50 μg/dose of MenPF-1 resulted in minor findings
at the injection site with foreign material-laden macrophages and giant cells noted. Polymor-
phonuclear and mononuclear inflammation with myofibre necrosis and/or regeneration, inter-
stitial fibrosis and/or mineralisation were also observed upon necropsy. Lumbar lymph node
enlargement was observed at necropsy and this correlated with lymphoid hyperplasia. Accu-
mulation of foreign material-laden macrophages and giant cells was also noted in the lumbar
lymph nodes. After a 4 week recovery period, a number of findings persisted in treated injec-
tion sites; however, these were of a lesser severity and frequency. There were no differences in
organ weight that were considered to be related to MenPF-1.
Whole genome sequencing for assessing impact of genetic
modifications on vaccine and evaluation strains
Comparative genomics of the draft genomes of the four strains used for vaccine production
and serological evaluation of the MenPF-1 vaccine (Table 5, S1 Fig) and the parent strain
showed that they were identical to each other at 1584 loci and differed at just six.
The first three locus differences were: a putative iron-uptake permease inner membrane
protein (locus NEIS0577); a cytosine-specific DNA methyltransferase (locus NEIS0771); a
putative membrane peptidase (locus NEIS1418). There was a single base pair difference in each
of the first two loci and a 240bp indel, and one base pair difference in the latter. The fourth
locus difference was at the NEIS1310 locus also known as modA the methylase modification
gene of the Neisseria type III restriction/modification system [30]. The presence of a certain
Fig 5. Morphological characterization. An example of bulk OMVs (batch MOX1106) derived from
Neisseria meningitidis strain SMenPF1.2 visualized by negative staining and transmission electron
microscopy (size bar is 500 nm). Courtesy of Sverre-Henning Brorson, Department of Pathology, University
of Oslo, Oslo, Norway.
doi:10.1371/journal.pone.0134353.g005
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number of the tandem repeat ‘AGCC’ can render the gene in frame (phase-variable ON) and
out of frame (phase-variable OFF). The two FetA-negative strains 3043 and 3311 were phase
variable ON. The highly variable pilE gene (locus NEIS0210) also differed amongst all strains
tested including these four. This was mainly due to variation in the C-terminal D region of the
gene; the class I type pilin in the case of these strains [31]. The pilS cassette region adjacent to
the pilE locus in each genome was the same in 3043, 3311 and for the fragment that was present
at the end of a contig for 3312 but differed by 21 bp and 7 bp in strains 2851 and 3207 respec-
tively in the fragments of contig that were aligned to the pilS cassette region allele 29. The pilE
alleles in each strain were possibly the result of recombination with different pilS cassettes:
Fig 7. Comparative immunogenicity betweenmouse species. Immunogenicity in three mouse species
(NIH, Balb/c, C57/Black), analyzed by ELISAmeasuring total IgG and IgG2 against rFetA, rPorA, or whole
cells (WC) of the vaccine strain 3207 (constitutive FetA expression and wt PorA expression). Two doses of
OMVs (2.5ug protein/dose with Al(OH)3 adjuvant) were given to mice s.c. 3 weeks apart, and these were bled
3 weeks after the final dose. N.S.; not significantly different. *; significant difference detected.
doi:10.1371/journal.pone.0134353.g007
Fig 6. Dose response immunogenicity. Potency dose response curve for three different batches of final
OMV vaccine product (FMOX1102, FMOX1105 and FMOX1107), as measured by OMV specific IgG ELISA.
Statistically significant differences were detected between batches at 1 μg (*) and 10 μg (**) dose levels
respectively but not for other dose levels.
doi:10.1371/journal.pone.0134353.g006
Meningococcal OMV Vaccine with Constitutive FetA Expression
PLOS ONE | DOI:10.1371/journal.pone.0134353 September 21, 2015 15 / 23
2851 and 3207 with cassettes 19 bp and 5 bp different to the pilS allele 5 from Helm and Seifert
retrieved from Genbank [32]. These pilS donor sequences were present unchanged in the frag-
ment of the pilS cassette region in their respective genomes. The resulting pilE alleles in strains
2851 and 3207 were atypical with an extended C terminal which may result in a non-functional
pilin subunit [31]. The remaining strains were putatively the result of recombination of pilS
cassette alleles 2 and 5 and possibly others. The FetA VR also differed in two of the strains (F1-
5 instead of F3-3) but this was due to the use of the plasmid pEAT2 [3] in the preparation of
the FetA knockouts which had the F1-5 VR. Remapping sequence reads using Bowtie and visu-
alization using Tablet showed lower read depth than surrounding regions of the genome in all
of these loci apart from pilE. Therefore, caution must be exercised when interpreting changes
in poly nucleotide tracts and tandem and complex repeat regions, features commonly associ-
ated with phase-variable and complex genes, from draft genomes assembled from short-read
data.
Discussion
Development and evaluation of the vaccine strain SMenPF1.2
The development of a capsular group B meningococcal vaccine with constitutive FetA expres-
sion was made possible by genetic modification of strain H44/76. Phenotypic characterisation
of the vaccine strain showed it to have a constitutive expression of FetA of ~7% of protein,
comparable to the highest level seen in OMVs derived from the wild-type strain H44/76. The
fetA gene is regulated by its native, iron-repressible promoter in wild-type H44/76 and conse-
quently FetA represents anything from one to eight percent of the total protein in wtOMV vac-
cines depending on culture conditions [16]. It is not clear if 7% is the maximum expression
level that can be stably attained for FetA in meningococcal outer membranes. Previous data
indicate that FetA expression can be at similar levels to those seen for PorA [10] and other
mechanisms for regulating FetA expression may achieve higher expression levels. Nevertheless,
the stable constitutive of expression of FetA was compatible with the use of the SMenPF1.2
strain to manufacture a vaccine.
Fig 8. SBA against the target strain panel in serum pools frommice immunised with 0, 2.5 μg or 10 μg
OMV protein, measured using 25% human complement.
doi:10.1371/journal.pone.0134353.g008
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Genomic effects of transformation of the vaccine strain and the
evaluation panel strains
The suitability of the vaccine evaluation strains to assess FetA and PorA-specific immunity was
verified in SBA against the 4 isogenic strains of the evaluation panel (Fig 9). Whole genome
sequencing of the vaccine and evaluation strain panel demonstrated that the genetic modifica-
tions also included changes outside of the PorA and FetA genes; hence, it is possible that some
bactericidal effects may not be attributable to the altered PorA and FetA expression levels
alone. The majority of differences were single base indels or tandem repeat differences associ-
ated with phase variation; however, many of these differences could be the result of sequencing
and/or assembly errors due to the nature of these complex and/or repetitive regions. The two
Fig 9. Impact of storage on vaccine immunogenicity. A. Stability of MenPF-1 final vaccine (lot
FMOX1102, FMOX1105 and FMOX1107), measured as potency at release, 12 months and 24 months of
storage at normal temperature (5°C). Potency, as measured by immunogenicity of a 2.5 μg OMV protein
dose in mice female, inbred NIH Ola/Hsd mice, 12–14 g. Statistically significant differences between
timepoints were observed for batches FMOX1105 (*) and FMOX1107(**). B. SBA against the target strain
panel in serum pools frommice immunised with MenPF-1 vaccine (batch MOX1102) on release (0), after 12
months storage (12 mo) or after 24 months storage (24 mo) at 5°C.
doi:10.1371/journal.pone.0134353.g009
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fetA knock-outs were phase variable ON for the type III restriction/modification system modi-
fication methylase [30] which may indicate some knock-on response to the genetic manipula-
tion of the fetA gene. The highly variable class I pilin gene pilE was different in each of the
isogenic strains in this study, underlining its ability to rapidly undergo antigenic diversification.
In a global collection of 219 isolates, a different class I sequence was found in each isolate [31].
This exceptional ability to diversify is mediated in individual strains through unidirectional
homologous recombination with multiple pilS cassettes located close to the pilE locus and was
demonstrated here [32] [33]. In summary, genome sequencing allowed for a high-resolution
investigation of genome changes that may have occurred as a result of genetic manipulation
and demonstrated that the isogenic strains showed remarkably little variation and were essen-
tially identical. The panel of strains was therefore appropriate to elucidate the respective contri-
butions to bactericidal activity of PorA and FetA specific antibodies.
Manufacturing process of MenB OMV vaccines—lessons learnt
The small scale manufacturing process for OMV production developed in this study resulted
in a consistent product, as indicated by quality control analyses of critical parameters. A stable
production process was established, which satisfied both GMP standards and resulted in a suf-
ficient production yield for testing OMV vaccines in phase I and II clinical trials. Advantages
Table 5. Genome Comparator analysis of isogenic strains.
Locus Gene product Strain identity Speciﬁcation of differences
H44/76
(Norwegian)
2851
(wild
type)
3043
(porA
+ fetA-)
3207
(SMenPF1.2)
3311
(porA-
fetA-)
3312
(porA-
fetA+)
PorA a PorA variable regions P1.7,16 P1.7,16 P1.7,16 P1.7,16 P1.7,16 P1.7,16
FetA a FetA variable region F3-3 F3-3 F1-5 F3-3 F1-5 F3-3 pEAT2 plasmid insert sequence
contains F1-5VR
NEIS0276 putative rotamase 147 100 100 100 100 100 18bp tandem repeat
‘TGCCAAAGTTGCCAAAGT’ allele-
147, 2x allele-100 3x
NEIS0308 hypothetical protein 14 16 16 16 16 16 1bp indel (allele-14 internal stop)
NEIS0568
(pglE)
glycosyl transferase 47 178 178 178 178 178 7bp tandem repeat ‘CAAACAA’
allele-178 12x, allele-47 23x (phase
variable OFF)
NEIS0577 putative iron-uptake
permease inner
membrane protein
1 1 1 1 80 1 1bp indel (allele-80 internal stop)
NEIS0771 cytosine-speciﬁc DNA
methyltransferase
1 1 1 1 1 17 1bp indel (allele-17 internal stop)
NEIS1310 type III restriction/
modiﬁcation system
modiﬁcation methylase
179 Off end
of
contig
254 179 254 179 4bp tandem repeat ‘AGCC’ allele-
179 18x (internal stop-phase-
variable OFF), allele-254 19x (ON),
2581(wt) 20x (OFF)
NEIS1418 putative membrane
peptidase
4 4 4 87 87 4 240bp indel and bp diff
NEIS1646 glycyl aminopeptidase 1bp del 4 4 4 4 4 1bp indel (H44/76 internal stop)
NEIS1998 phosphopantetheine
adenylyltransferase
1bp del 4 4 4 4 4 1bp indel (H44/76 out of frame)
NEIS0210
(pilE)
pilE protein 20 442 off end
of contig
443 440 444
a Listed are the two variable regions of the two genetically modiﬁed genes porA and fetA and the loci where there were sequence differences.
doi:10.1371/journal.pone.0134353.t005
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with the production methods employed were that they were simple, reproducible, and compat-
ible with criteria for safe handling of genetically modified organisms (GMOs) [18]. The protein
yield in in this small scale process (mean 0.79 mg protein per L growth medium) was lower
than observed for other OMV vaccine processes. Factors affecting the yield probably included
the critical micelle concentration (detergent concentration) affecting the ability of the OMVs
to pass the sterility filter. The hydrophobicity and electric charge exerted by the CFF mem-
brane, as well as the salt concentration of the buffer (zeta potential) were parameters likely to
be connected with the dispersion and formation of vesicles [34]. Despite differences in the pro-
duction processes in Norway, The Netherlands, and Cuba [17,18,35], the various OMV vac-
cines produced in these countries have similar safety profiles [36], whereas their ability to
induce SBA may differ. The latter may be related to various factors, including the target strain
used in the SBA assay and the relative amount of LPS in the vaccine; a potent immune stimula-
tor. The current 9 litre-scale process was used to manufacture three batches of vaccine, each of
sufficient yield and containing a consistent amount of the PorA and FetA antigens. Each batch
contained a similar amount of LPS to other OMV vaccines and met Ph. Eur requirements for
endotoxin content (<105 IU/mL as measured by LAL gel clot assay).
Immunogenicity and stability
The final product was highly immunogenic in potency tests in NIH mice, demonstrating a
dose-response curve (Fig 8). Comparative immunogenicity across three mouse strains showed
a strong response measured in ELISA against PorA and no significant response against FetA
(Figs 8 and 9). This discrepancy between PorA and FetA responses was consistent with the fact
that, within the administered dose of 2.5 μg total OMV protein, approximately 0.54 μg (21.7%)
of this was PorA and 0.19 μg (7.7%) was FetA. Bactericidal antibody testing of serum pools
from mice immunized as part of potency testing in batch release and stability testing showed
that there was practically no contribution of FetA to the bactericidal activity observed (Figs 8
and 9). The immunogenicity of both PorA and FetA has been well documented in previous
studies, and in particular the role of IgG against PorA in inducing protective antibodies in
humans. This latter aspect is not as well characterised for FetA, and will be important to estab-
lish in a phase I clinical trial with the MenPF-1 vaccine. The vaccine evaluation panel described
in this study will be instrumental to delineate the ability of anti-FetA IgG to mediate bacteri-
cidal activity.
The product was stable, meeting the same identity and purity specifications after 24 months
as upon release. Although ELISA-based potency results varied during the observation period
(Fig 9), results from SBA performed on pools of sera from mice immunized with MenPF-1
batches stored for up to 24 months did not suggest any decline in the functional antibody effect
(Table 3 and Fig 9). Previous studies indicate that aluminium-adjuvanted deoxycholate
extracted OMV vaccines are stable for at least 1 year [18,37], and the shelf-life of the MenPF-1
vaccine was consistent with this.
Toxicological evaluation of the MenPF-1 OMV vaccine
The toxicological profiling of rabbits exposed to 4 intramuscular injections of the MenPF-1
vaccine (i.e. one more than typically administered with the MeNZB and MenBvac OMV vac-
cines in adults) showed inflammation at the injection site, as well as lymph node enlargement
and other signs indicative of an inflammatory response (S1 Text). This was in line with treat-
ment-related findings typically seen in repeat-dose studies with parenterally administered vac-
cines, as recently reviewed [38]. Changes observed in this type of studies are typically not
severe and are transient. The strong anti-OMV IgG response mounted following
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administration of MenPF-1 indicates the relevancy of the rabbit model and the doses used for
assessing toxicology. The findings are also consistent with previous experience using alumin-
ium adjuvanted vaccines, with expected presence of local inflammation. In addition to boosting
the immunological response, another role of the adjuvant for OMVs is to adsorb the free LPS
and hence reduce the toxicity of the dOMVs. Ultimately, the vaccine was considered to be well
tolerated, if moderately reactogenic, and satisfied the E.U. requirements for testing in a phase I
clinical trial [39].
Future role of OMV vaccines in prevention of meningococcal disease
Major strengths of using detergent-extracted OMVs from wild-type meningococci as vaccine
formulations are that they: (i) are immunogenic and protective, inducing functional antibodies,
and (ii) have an established track record of safe effective use in humans. Recent data on the
safety and efficacy of the MeNZB OMV vaccines in clinical use in New Zealand supports our
manufacturing process as a platform technology for vaccine development [36]. MenB vaccine
development has in the last decade focused on recombinant OMPs and native OMV vaccines;
however, recombinant proteins were found to be more immunogenic when combined with a
dOMV [35]. The recently licensed four component vaccine (4CMenB), consists of similar
OMVs to the MeNZB vaccine combined with three recombinant protein antigens identified
from meningococcal genome sequence data. Although the performance of a novel MenB vac-
cine to a large extent can be estimated based on epidemiological mapping, a clinical trial of the
MenPF-1 OMV vaccine should be pursued to enable assessment of FetA specific responses in
humans.
The MenPF vaccine concept
The rationale underpinning the MenPF vaccine is that epidemiological data indicate that the
meningococcal PorA and FetA antigens exhibit repertoire structuring and diversity consistent
with their generating a protective human immune response in vivo [8]. Although the extensive
repertoire of these antigens presents an apparent problem for the design of a broadly cross-pro-
tective vaccine that include these antigens, the repertoire structuring apparent in natural popu-
lation of meningococcal is such a that a multivalent vaccine consisting of relatively few variants
has the potential to offer a high level of coverage of invasive meningococci [7]. This approach
contrasts with the development of the currently licensed recombinant protein-based vaccines
(4CMenB and the RP2086 fHbp), in which the antigenic components were chosen from a sin-
gle untypical isolate and subsequently assessed for their ability to elicit cross-reactive
antibodies.
The current study was a first step in the proof-of-concept for the MenPF approach to the
prevention of meningococcal disease. We were not able to define a separate contribution of
FetA-specific antibodies to the bactericidal response to the vaccine through the immunogenic-
ity studies here described. This could be further studied by assessing other target strains in SBA
with a heterologous PorA, controlling for the variable wt FetA expression if possible. Secondly
adsorption of sera with rFetA could prove useful. Finally, the bactericidal effect of FetA anti-
bodies could be part of a synergistic SBA effect and be masked by other antibodies in combina-
tion in the SBA. A separate study demonstrated that one to four immunizations of mice with
2.5 μg protein per dose induced a small but significantly higher SBA GMT against the vaccine
strain SMenPF1.2 compared to against the strain 3043 (FetA off, PorA wt) when assessed using
rabbit complement, but not with human complement [Sanders et al. Manuscript PONE-D-14-
43371, in revision]. The same study further showed that human complement SBA GMTs were
higher against the vaccine strain SMenPF1.2 than against the FetA wild type strain H44/76; the
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latter expressing a lower level of FetA. The current study has demonstrated that the MenPF-1
vaccine likely is suitably safe for testing in a clinical phase I trial, and the study by Sanders et al.
that FetA specific antibodies induced following vaccination may have a small but significant
role in conferring bactericidal antibodies following MenPF vaccination. On the basis of previ-
ous studies with the MenBvac OMV vaccine [35], a high seroconversion rate with anti-PorA
IgG induced will likely be observed with the MenPF-1 vaccine in a clinical trial. A key focus
will however be to study the relative contribution of FetA antibodies to the induction of protec-
tive immunity. We have recently proceeded to evaluate this vaccine in phase I human studies
with the data supporting the safety and immunogenicity of this approach, and demonstrating
the induction of FetA bactericidal antibodies in humans [40] Further studies are required to
investigate the species-specific differences of the ability of FetA to induce bactericidal antibod-
ies, and to which extent the FetA dose level and source of complement affects this evaluation.
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